In short
Clinical trials investigating ACICLOVIR SODIUM are studying its use in people with relapsing-remitting multiple sclerosis. These trials aim to evaluate safety and how well the treatment plan works, especially in adults with disease duration under 10 years.
Key points
- Clinical trials investigating ACICLOVIR SODIUM are focused on relapsing-remitting multiple sclerosis. The listed study is a Phase 2 interventional trial with 50 planned participants and an authorised status. It targets patients with less than 10 years of disease duration. The main goal is to check whether the rate of treatment-related serious adverse events is acceptably low. The primary outcome uses a yes-or-no measure for at least one serious event in each participant.
Trial overview
The available trial data describe one interventional study of ACICLOVIR SODIUM in people with relapsing-remitting multiple sclerosis. The study is titled HiHat trial and is listed as authorised.
This trial is not presented as a general drug monograph. It is specifically about a clinical research project that is testing a treatment plan and measuring safety in a defined patient group.
Who is being studied
The target population is patients with relapsing-remitting multiple sclerosis and less than 10 years of disease duration. This means the study focuses on people whose disease has been present for a shorter time, rather than those with long-standing disease.
The trial plan includes 50 participants. This is a relatively small group, which is common in early clinical research when researchers are still checking safety and early signals of benefit.
Trial design and phase
The study is an interventional trial, which means the research team assigns the treatment plan rather than only observing usual care. It is in Phase 2, a stage that usually looks more closely at safety and early effectiveness in a selected patient group.
The brief summary says the main objective is to evaluate whether the serious adverse event rate associated with sequential treatment of rituximab followed by cladribine is acceptably low. In simple terms, the study is checking whether serious medical problems linked to the treatment plan happen at a low rate.
What is being measured
The primary outcome is the binary indicator of at least one treatment-related serious adverse event per participant. A binary indicator is a yes-or-no result, so each participant is counted as either having had at least one such event or not.
The phrase treatment-related means the researchers think the event may be connected to the study treatment. The phrase serious adverse event means a serious medical problem that happens during the study.
Study treatment plan
The intervention list includes ACICLOVIR, cetirizine, methylprednisolone, rituximab, cladribine, sulfamethoxazole and trimethoprim, and paracetamol. The brief summary specifically links the safety question to sequential treatment with rituximab followed by cladribine.
For patients, the important point is that the trial is evaluating a treatment sequence, not just one single medicine. The study is asking whether this planned sequence can be given with an acceptably low rate of serious treatment-related problems.
Key patient terms
Authorised means the trial has approval to proceed. Enrollment means the planned number of participants who will join the study.
Sequential treatment means one treatment is given after another in a set order. Primary outcome means the main result the researchers want to measure.